CDK4/6 + Endocrine therapy

DRUG2 trials

Sponsors

Washington University School of Medicine, University of California, San Diego

Conditions

ER+, HER2-, Metastatic Breast CancerMetastatic Breast CancerMetastatic Invasive Breast CancerResistant Breast CancerUnresectable Breast Cancer

Phase 2

Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer

Not yet recruitingNCT07729046

University of California, San DiegoER+, HER2-, Metastatic Breast Cancer, Metastatic Invasive Breast Cancer, Resistant Breast Cancer

Start: 2027-07-01End: 2035-06-01Target: 150Updated: 2026-07-27

Unknown Phase

BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer

RecruitingNCT05977036

Washington University School of MedicineMetastatic Breast Cancer, Unresectable Breast Cancer

Start: 2024-09-25End: 2034-09-30Target: 65Updated: 2025-12-17